Immix Biopharma (IMMX) Operating Expenses (2021 - 2026)
Immix Biopharma (IMMX) posted Operating Expenses of $10.8 million for Q1 2026, down 0.82% sequentially from $10.9 million in Q4 2025, and up 130.71% YoY from $4.7 million in Q1 2025.
Immix Biopharma (IMMX) Operating Expenses (2021 - 2026) Analysis & Trends
Immix Biopharma has reported Operating Expenses for 6 years, with the latest figure at $10.8 million in Q1 2026.
- Quarterly Operating Expenses rose 130.71% year-over-year to $10.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $36.1 million (up 65.74% YoY) and the FY2025 annual result came in at $30.0 million, up 32.11% from the prior year.
- Operating Expenses fell to $10.8 million in Q1 2026 per IMMX's latest filing, from $10.9 million in the prior quarter.
- Over five years, Operating Expenses peaked at $10.9 million in Q4 2025 and troughed at $1.3 million in Q1 2022.
- A 5-year average of $5.2 million and a median of $4.7 million in 2024 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2022 and 2025: Operating Expenses soared 718.38% in 2022, then fell 16.23% in 2025.
- Over 5 years, Operating Expenses stood at $3.8 million in 2022, then jumped by 41.67% to $5.4 million in 2023, then decreased by 7.23% to $5.0 million in 2024, then soared by 118.43% to $10.9 million in 2025, then dropped by 0.82% to $10.8 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $10.8 million, $10.9 million, and $7.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Immix Biopharma | 784.75 Mn | 784.75 Mn | - | 12.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.46 Mn |
| Mar 31, 2026 | 10.80 Mn |
| Dec 31, 2025 | 10.89 Mn |
| Sep 30, 2025 | 7.66 Mn |
| Jun 30, 2025 | 6.72 Mn |
| Mar 31, 2025 | 4.68 Mn |
| Dec 31, 2024 | 4.99 Mn |
| Sep 30, 2024 | 7.39 Mn |
| Jun 30, 2024 | 4.70 Mn |
| Mar 31, 2024 | 5.59 Mn |
| Dec 31, 2023 | 5.38 Mn |
| Sep 30, 2023 | 4.52 Mn |
| Jun 30, 2023 | 3.72 Mn |
| Mar 31, 2023 | 2.52 Mn |
| Dec 31, 2022 | 3.79 Mn |
| Sep 30, 2022 | 1.53 Mn |
| Jun 30, 2022 | 1.56 Mn |
| Mar 31, 2022 | 1.33 Mn |
| Dec 31, 2021 | 598,338.00 |
| Sep 30, 2021 | 347,991.00 |